Panitumumab
Other name
-
International/Other brands
Vectibix
Groups
Approved
Structure
Prescription products
| Name | Dosage | Strength | Route | Labeller |
|---|---|---|---|---|
| Vectibix | Solution | 400 mg/20mL | Intravenous | Amgen |
| Vectibix | Solution | 200 mg/10mL | Intravenous | Amgen |
| Vectibix | Injection, solution, concentrate | 20 mg/ml | Intravenous | Amgen Europe B.V. |
| Vectibix | Solution | 200 mg | Intravenous | Amgen |
| Vectibix | Solution | 100 mg/5mL | Intravenous | Amgen |
| Vectibix | Solution | 100 mg | Intravenous | Amgen |
| Vectibix | Solution | 400 mg | Intravenous | Amgen |
Target
Description
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Indications
Metastatic Colorectal Cancers
Other indications
-
Mechaism of action
-
Absorption
-
Metabolism
-
Toxicity
Panitumumab was shown to cause skin, ocular and mucosal related toxicities in 90% of patients receiving panitumumab. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage, were reported.